Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

医学 达布拉芬尼 内科学 临床终点 不利影响 肺癌 人口 肿瘤科 临床试验 癌症 临床研究阶段 队列 胃肠病学 外科 曲美替尼 威罗菲尼 激酶 MAPK/ERK通路 环境卫生 细胞生物学 生物 转移性黑色素瘤
作者
David Planchard,Tae Min Kim,Julien Mazières,Élisabeth Quoix,Gregory J. Riely,Fabrice Barlési,Pierre‐Jean Souquet,Egbert F. Smit,Harry J.M. Groen,Ronan J. Kelly,Byoung Chul Cho,Mark A. Socinski,Lini Pandite,Christine Nase,Bo Ma,Anthony M. D’Amelio,Bijoyesh Mookerjee,C. Martin Curtis,Bruce E. Johnson
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:17 (5): 642-650 被引量:432
标识
DOI:10.1016/s1470-2045(16)00077-2
摘要

Activating BRAF(V600E) (Val600Glu) mutations are found in about 1-2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in these patients. Dabrafenib is an oral selective inhibitor of BRAF kinase. We did a trial to assess the clinical activity of dabrafenib in patients with advanced non-small-cell lung cancer (NSCLC) positive for the BRAF(V600E) mutation.In this phase 2, multicentre, non-randomised, open-label study, we enrolled previously treated and untreated patients with stage IV metastatic BRAF(V600E)-positive NSCLC. Patients received oral dabrafenib 150 mg twice daily. The primary endpoint was investigator-assessed overall response, which was assessed in patients who had received at least one dose of dabrafenib; safety was also assessed in this population. The study is ongoing but not enrolling patients in this cohort. This trial is registered with ClinicalTrials.gov, number NCT01336634.Between Aug 3, 2011, and Feb 25, 2014, 84 patients were enrolled, six of whom had not previously received systemic treatment for NSCLC. 26 of the 78 previously treated patients achieved an investigator-assessed overall response (33% [95% CI 23-45]). Four of the six previously untreated patients had an objective response. One patient died from an intracranial haemorrhage that was judged by the investigator to be due to the study drug. Serious adverse events were reported in 35 (42%) of 84 patients. The most frequent grade 3 or worse adverse events were cutaneous squamous-cell carcinoma in ten (12%), asthenia in four (5%), and basal-cell carcinoma in four (5%).Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC. Our findings suggest that dabrafenib could represent a treatment option for a population of patients with limited therapeutic options.GlaxoSmithKline.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
369ninja发布了新的文献求助10
刚刚
8895发布了新的文献求助10
2秒前
3秒前
4秒前
JamesPei的应助被dianhuaxue采纳,获得10
4秒前
4秒前
小馋猫完成签到,获得积分10
5秒前
yang发布了新的文献求助10
6秒前
liu1223456完成签到,获得积分10
6秒前
ihuu完成签到,获得积分10
6秒前
李健的应助被耳东采纳,获得10
7秒前
8秒前
可爱的函函的应助被勿忘采纳,获得10
8秒前
13完成签到 ,获得积分10
8秒前
8秒前
刘桑完成签到,获得积分10
12秒前
12秒前
12秒前
13秒前
xx完成签到,获得积分10
14秒前
Lemon完成签到,获得积分10
14秒前
15秒前
yang发布了新的文献求助10
15秒前
大方元风发布了新的文献求助10
15秒前
Lu发布了新的文献求助10
16秒前
Ava的应助被蛟jiao采纳,获得10
18秒前
18秒前
cc发布了新的文献求助100
18秒前
sfliufighting发布了新的文献求助10
19秒前
个性成风完成签到 ,获得积分10
19秒前
19秒前
SciGPT的应助被速写采纳,获得10
19秒前
19秒前
勇气大爆发完成签到,获得积分10
19秒前
耳东发布了新的文献求助10
20秒前
思恋欢发布了新的文献求助10
21秒前
vivi完成签到,获得积分10
21秒前
21秒前
科研通AI6.4的应助被wu采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817